Sirnaomic Mediaroom - PR Newswire APAC

Sirnaomics Announces 2023 Annual Results

Focuses on the Consolidation for Leading Projects Accelerates Clinical Trials for Core Products ST...

2024-03-28 17:09 3878

Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors

Study published in NAR Cancer, a leading peer-reviewed journal in the field of nucleic acid therape...

2024-01-24 17:49 1378

RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770

GERMANTOWN, Md and GUANGZHOU, China, Dec. 18, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", ...

2023-12-18 22:04 1805

Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 6, 2023 /PRNewswire/ --Sirnaomics Ltd....

2023-12-06 01:01 1725

Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer

HONG KONG, Germantown, Md. and Suzhou, China, Dec. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Co...

2023-12-01 14:41 1671

Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction

The Group is Advancing the Program to a Phase II Clinical Study Data presented at the 2023 Fall Cli...

2023-11-01 22:07 1735

Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

* Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intr...

2023-08-31 11:30 4265

Sirnaomics Announces 2023 Interim Results

Positive Clinical Readouts Validate Potential of Proprietary Delivery Platforms and Cement Global L...

2023-08-31 10:40 3875

Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

HONG KONG, Germantown, Md. and SUZHOU, China, July 28, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "C...

2023-07-28 11:56 1965

Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences

HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Co...

2023-07-12 20:45 2352

Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, July 5, 2023 /PRNewswire/ --Sirnaomics Ltd....

2023-07-05 23:07 2302

Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Co...

2023-06-19 21:29 3650

Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 14, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Co...

2023-06-14 00:42 2391

Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Sirnaomics Ltd.(the "Com...

2023-06-05 19:12 2691

Sirnaomics Dosed the First Patient in Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

HONG KONG, Germantown, Md. and Suzhou, China, June 2, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Co...

2023-06-02 00:06 6681

Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, May 17, 2023 /PRNewswire/ -- Sirnaomics Ltd...

2023-05-17 21:13 2792

RNAimmune Receives FDA Clearance of Investigational New Drug Application for Phase 1 Trial of RV-1730 COVID-19 Booster Vaccine

GERMANTOWN, Md. and GUANGZHOU, China, April 28, 2023 /PRNewswire/ -- RNAimmune, Inc.(the "Company" ...

2023-04-28 00:29 2746

Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program

Study commences following green light from the U.S. FDA for Investigational New Drug Application H...

2023-04-12 16:25 2295

Sirnaomics Announces 2022 Annual Results

Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therap...

2023-03-28 19:26 6423

Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, March 20, 2023 /PRNewswire/ -- Sirnaomics L...

2023-03-20 23:27 2234

Latest News